BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
- None.
- None.
Insights
A patent grant for a pharmaceutical compound, such as BF-223, is a critical step in securing a competitive advantage in the drug development industry. The legal protection afforded by the Australian Patent No. 2019216757 not only safeguards BullFrog AI's intellectual property but also provides a strategic asset that could be leveraged in negotiations with potential partners or licensees. As a Pharmaceutical Patent Attorney, it is evident that the company has established a barrier to entry for competitors in the Australian market, which could be a significant factor in the valuation of the company's portfolio.
Additionally, the improvement in solubility and oral bioavailability represents a substantial advancement over the parent compound, mebendazole, which could translate into better patient outcomes and compliance. This patent could also serve as a precedent for future filings in other jurisdictions, potentially creating a global shield for BullFrog AI's assets and contributing positively to the company's market positioning.
The development of prodrugs like BF-223 is a testament to the innovative approaches being taken to overcome pharmacokinetic challenges in oncology. As an Oncology Drug Development Expert, the reported enhancement in solubility and bioavailability is particularly noteworthy. These properties are crucial for the efficacy of anticancer drugs, as they directly influence the drug's ability to reach and impact the tumor site.
Preclinical success in an animal model for glioblastoma also suggests that BF-223 has the potential to address a significant unmet medical need. Glioblastoma is a notoriously difficult cancer to treat and advancements in this area could lead to considerable patient benefit. Furthermore, the anticipation of patent issuance in additional territories indicates a strategic approach to intellectual property that could support future clinical trials and partnerships, thereby potentially accelerating the drug's time-to-market and impacting BullFrog AI's growth trajectory.
From a financial perspective, the issuance of a patent such as this can be a catalyst for a company's stock performance. A Financial Analyst would recognize that BullFrog AI's announcement may lead to positive investor sentiment, as it not only demonstrates progress in the company's pipeline but also suggests a potential for exclusive market rights and future revenue streams. The focus on strategic partnerships to monetize the asset further underscores the company's commitment to capitalizing on its research and development efforts.
However, it is important to note that the journey from patent protection to marketable product is fraught with regulatory hurdles and clinical trial risks. Investors should consider the long-term investment required for drug development against the backdrop of the patent's life and the competitive landscape of oncology treatments. The company's ability to navigate the subsequent phases of development will be critical in realizing the value of the patent grant.
Issued patent provides protection for BF-223 and related compounds
GAITHERSBURG, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that the Australian Patent Office has issued Patent No. 2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. This follows the July 2023 announcement of the issuance of U.S. Patent No. 11,712,435 for this invention (link), with issuance of patents expected in additional territories in the future.
The patented compounds exhibit improved solubility and oral bioavailability relative to the parent drug, thereby addressing a key difficulty associated with the potential use of mebendazole for oncology indications, and include BF-223, a key asset in the Company’s pipeline of in-licensed drugs. The Company previously announced positive results from a preclinical study demonstrating that BF-223 has anticancer activity in an animal model for glioblastoma (link).
"This patent grant further strengthens intellectual property protection of this key asset in our pipeline," said Vin Singh, founder and CEO of BullFrog AI. "Mebendazole has shown promise in treating various types of cancer, and the results of our preclinical study evaluating BF-223 in an animal model of glioblastoma support our thesis that prodrugs of mebendazole may provide enhanced therapeutic potential, thereby improving the likelihood of clinical success. We look forward to working with strategic partners to monetize this promising asset for the treatment of glioblastoma and other oncology indications."
About BullFrog AI
BullFrog AI is a technology-enabled drug development company using AI and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.
For more information visit BullFrog AI at:
Website: https://bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Investors
Dave Gentry
RedChip Companies, Inc.
BFRG@redchip.com
800-733-2447
SOURCE: BullFrog AI Holdings, Inc.
FAQ
What is the ticker symbol for BullFrog AI Holdings, Inc.?
What is the patent number issued by the Australian Patent Office to BullFrog AI Holdings, Inc.?
What are the key assets in the Company’s pipeline of in-licensed drugs?
What type of study demonstrated the anticancer activity of BF-223?
What is the potential use of mebendazole for oncology indications?
